This 1 Marijuana Stock Has the Highest Chance to Recover in 2020

With the carnage the Canadian marijuana industry has been facing since last year, Aphria stock has a strong chance of coming out as a survivor.

edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

The fun industry of recreational marijuana didn’t have any fun in the stock market last year. The most influential players in the game were beaten to the ground. Aurora Cannabis, one of the largest marijuana companies, went down 59% in market value. Even Canopy Growth, the company with the most robust balance sheet, went down by 25%. But the dark cloud hovering over the green industry might finally be giving way to some sunshine.

The second phase of marijuana legalization, Cannabis 2.0, was completed late last year. It was supposed to turn things around for the whole marijuana industry. It didn’t completely transform the weed landscape, but it has started the process. Market values of marijuana companies have finally begun to climb up; though it’s hard to say whether or not the companies will see the former glory in 2020.

What can be said is that Aphria (TSX:APHA)(NYSE:APHA) has the best chance of recovery this year. Let’s look at the reasons why.

This stock has fallen the least

In terms of market cap, Aphria, with a market cap of $1.71 billion, is the fourth-largest marijuana company in the country, behind Canopy Growth, Aurora, and Cronos. In 2019, Apria’s stock fell by 13.6%, which is by far the least in the sector. In the last month, Aphria’s 10% growth is second only to Canopy’s — a company more than five times the size of Aphria.

This indicates that even when Aphria was being dragged down by the whole failing sector, it managed to stay a bit above the surface, and managed to keep more investor confidence than most of its peers.

Some good numbers

In terms of quarterly revenue growth, Aphria was heads and shoulders above other marijuana companies. Its 848% growth is easily four times that of the other three. Aphria also remained profitable in four out of its last five quarters.

Like the other four big marijuana companies, Aphria’s EBITDA is also negative. But its negative $22.7 million is a relatively tiny number compared to others. The company is also the least-diluted company among the four, with 252 million shares outstanding. For a company of its magnitude, Aphria has relatively low debt, and the company’s cash flows are almost equal to its debt.

Focus and diversification

Aphria has shifted its focus to medical-grade tetrahydrocannabinol, or THC. This product has been one of the core reasons for the company’s profitable last quarters. The company is also looking to drive about 40% of its revenue from recreational marijuana products, like vapes, edibles, and beverages, going forward.

Aphria is set to become a market leader when it comes to production capacity, with project outputs reaching over a quarter-million kilograms per year.

When it comes to diversification, the company has most of its foreign stake in one major market: Germany. Aphria is building an 8,000 sq. metre facility for medical cannabis production.

Foolish takeaway

Things are looking much better for the cannabis industry in 2020. Most of the marijuana companies might take some time to regain the momentum, but the chances of Aphria moving ahead and leaving others in the dust are relatively high. So, if you want to start 2020 with a small green plant, you might want to check out Aphria’s pot.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Adam Othman has no position in any of the stocks mentioned.

More on Cannabis Stocks

Cannabis grows at a commercial farm.
Cannabis Stocks

Why Canopy Growth Stock Could Double in 2024

Canopy Growth (TSX:WEED) stock saw its share more than double in the last two weeks. So, can it do it…

Read more »

Coworkers standing near a wall
Cannabis Stocks

Why Is Everyone Talking About Canopy Growth Stock?

Canopy Growth stock (TSX:WEED) saw shares surge in the last two weeks for a variety of reasons investors can dig…

Read more »

Pot stocks are a riskier investment
Stocks for Beginners

Why Shares of Cannabis Stocks Are Rising This Week

Cannabis stocks received a boost this week as the White House urged the drug enforcement administration to reschedule the drug.

Read more »

A person holds a small glass jar of marijuana.
Stocks for Beginners

Why Canopy Growth Stock Jumped 16% on Wednesday

Canopy Growth stock (TSX:WEED) is up 16% on Wednesday, adding to a surge of 60% growth in the last week…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Is the Worst Over for Canopy Growth Stock?

Down 99% from all-time highs Canopy Growth stock has burnt investor wealth and remains a high-risk investment.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Steer Clear: This Stock Spells Trouble

A newly listed cannabis stock is outperforming in 2024 but investors should stay clear to avoid trouble and losses.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

2 Best Marijuana Stocks to Buy This Month

Marijuana stocks in the U.S. such as Green Thumb and Curaleaf can help you deliver outsized gains to investors in…

Read more »

A cannabis plant grows.
Cannabis Stocks

Can Aurora Cannabis Stock Recover in 2024?

Aurora Cannabis stock is down 99% from all-time highs but remains a high-risk bet, despite its cheap valuation.

Read more »